Drug Search Results
More Filters [+]

Squalamine

Alternative Names: squalamine
Latest Update: 2024-01-10
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Angiogenesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Genaera
Company Location: PLYMOUTH MEETING PA 19462
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Squalamine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Macular Degeneration|Wet Macular Degeneration|Choroidal Neovascularization

Phase 2: Wet Macular Degeneration|Macular Degeneration|Ovarian Cancer|Retinal Neovascularization|Diabetic Retinopathy|Prostate Cancer|Retinal Vein Occlusion|Choroidal Neovascularization|Macular Edema

Phase 1: Amyotrophic Lateral Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12619000375156

P1

Completed

Amyotrophic Lateral Sclerosis

2018-11-06

MAKO

P3

Unknown status

Macular Degeneration

2017-12-01

OHR-1501

P2

Withdrawn

Wet Macular Degeneration

2016-04-01

Ohr-005

P2

Withdrawn

Diabetic Retinopathy|Macular Edema

2015-09-01

Recent News Events